Everest Medicines Limited (6HN.F)
| Previous close | 2.7400 |
| Open | 2.7200 |
| Bid | 2.8600 x N/A |
| Ask | 3.0400 x N/A |
| Day's range | 2.7200 - 2.7200 |
| 52-week range | 1.2100 - 3.6600 |
| Volume | |
| Avg. volume | 215 |
| Market cap | 937.448M |
| Beta (5Y monthly) | 2.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireEverest Medicines Announces Financial Results for Full Year Ended December 31, 2023
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for the full year ended December 31, 2023, along with a corporate update.
PR NewswireEverest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Singapore Health Sciences Authority (HSA) has approved NEFEGAN® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. NEFEGAN®, known in other Everest territories as Nefecon®, was the first ever treatment for IgAN full
PR NewswireEverest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.
